Tool to Improve Treatment Adherence and Outcomes at Grady Liver Clinic

NCT ID: NCT03831555

Last Updated: 2019-02-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-05

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn more about what psychological and social factors affect people in how they take their hepatitis C medications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of this study is to determine if a qualitative survey that assesses a patient's readiness for treatment of Hepatitis C (HCV) and associated interventions based on identified barriers can improve treatment adherence and outcomes. HCV remains a leading cause of liver cancer and end stage liver disease despite greater than 90% cure rates with new, all-oral antiviral medications. While these new medications are easier to tolerate and access than previous treatment regimens, medication adherence still remains a great barrier to cure. In this study, we will administer the Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool, a free, online survey developed at the Mount Sinai School of Medicine to determine psychosocial readiness for treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PREP-C

The research assistant will complete the abbreviated PREP-C survey with the study participants either before or after their medical appointment. The PREP-C tool is accessed online at https://prepc.org/.

Group Type ACTIVE_COMPARATOR

PREP-C

Intervention Type BEHAVIORAL

The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool assesses a patient's psychosocial readiness to start HCV treatment. There are nine sections in the survey:

1. Motivation: reasons client wants to begin HCV treatment, concerns about treatment, and the importance of treatment
2. Information: knowledge about HCV treatment and one's own HCV disease status
3. Medication Adherence: current prescribed medications and adherence to them in the prior month
4. Self-efficacy: self-confidence about adhering to HCV treatment
5. Social Support and Stability: stability of financial, housing, and social support resources
6. Alcohol and substance use: alcohol and substance use behaviors and current treatment
7. Psychiatric Stability: current psychiatric status, previous and current treatment
8. Energy Level: sleep and fatigue
9. Cognitive Functioning: perceived difficulty with communication in health care setting, problem-solving ability, and memory.

Standard of care

Participants will receive the standard of care (usual care) for chronic HCV infection.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PREP-C

The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool assesses a patient's psychosocial readiness to start HCV treatment. There are nine sections in the survey:

1. Motivation: reasons client wants to begin HCV treatment, concerns about treatment, and the importance of treatment
2. Information: knowledge about HCV treatment and one's own HCV disease status
3. Medication Adherence: current prescribed medications and adherence to them in the prior month
4. Self-efficacy: self-confidence about adhering to HCV treatment
5. Social Support and Stability: stability of financial, housing, and social support resources
6. Alcohol and substance use: alcohol and substance use behaviors and current treatment
7. Psychiatric Stability: current psychiatric status, previous and current treatment
8. Energy Level: sleep and fatigue
9. Cognitive Functioning: perceived difficulty with communication in health care setting, problem-solving ability, and memory.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* seen in the Grady Liver Clinic during the study time period
* have a confirmed chronic hepatitis C infection (hepatitis C antibody positive and detectable hepatitis C viral load)

Exclusion Criteria

* no chronic hepatitis C infection
* co-infection with HIV or hepatitis B
* non-English speaking
* unable to consent to participate
* already started HCV therapy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Emory University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lesley Miller

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lesley Miller, MD

Role: PRINCIPAL_INVESTIGATOR

Emory University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Grady Liver Clinic

Atlanta, Georgia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB00093687

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hepatitis C Self-Management
NCT00328042 COMPLETED NA
Way to Cure HCV Adherence
NCT02472925 COMPLETED NA